Further exploration could lead to strategies for its use in age-related atrophy and impaired regeneration, although at this stage we have not provided direct evidence that LASSS oral-supplementation can mitigate sarcopenia or has therapeutic value, awaiting the results of aging experiments
A novel triple GIP, GLP-1, and glucagon receptor agonist (LY3437943) in people with type 2 diabetes
Important: CJC-1295 and Ipamorelin are research/compounded peptides and are not FDA-approved as a weight-loss or anti-aging drug
Titration step values follow the REDEFINE Phase 3 protocol structure as reported by Novo Nordisk and the NEJM publications
Combined with CJC-1295s GHRH analogue action, the two peptides create a synergistic effect: CJC-1295 stimulates growth hormone release directly, while Ipamorelin amplifies this signal by acting on the same receptor pathways
For patients who want the data, we can add an optimization panel to track markers and refine the protocol over time